Heavy drinking in young adults tied to endocannabinoid pathway

Philadelphia January 18, 2023

Although heavy drinking in young adulthood increases the risk for alcohol use disorder (AUD), not all young heavy drinkers go on to develop AUD, globally the most common substance use disorder. Research has shown that individual differences in alcohol sensitivity and cardiovascular responses may predict drinking patterns and progression to AUD. Little is known, however, about the brain-based mechanisms of AUD vulnerability – a better understanding of which could guide preventive interventions against AUD. A new study explores the role of endocannabinoid levels in hazardous alcohol use. The study appears inBiological Psychiatry, published by Elsevier.

Led by Isabelle Boileau, PhD, at the Centre for Addiction and Mental Health and University of Toronto, the new study explores the relationship between fatty acid amide hydrolase (FAAH) levels in heavy drinking youth and alcohol intake, drinking patterns, differential responses to alcohol, and family history of AUD. The researchers hypothesized that lower brain FAAH levels would correlate to heavier and more hazardous drinking.

FAAH is an enzyme that degrades the endogenous cannabis-like substance anandamide, a neurotransmitter that activates the cannabinoid 1 receptor (CB1) and is involved in the regulation of pain, appetite, and mood. Endocannabinoid activity specifically in the brain’s striatum and prefrontal cortex regions is thought to modulate the rewarding effects of alcohol. Studies in animals and people have suggested that reduced FAAH activity leads to increased alcohol seeking and consumption and decreased negative effects of intoxication.

The researchers used positron emission tomography imaging of [11C]CURB, a highly specific radiotracer for FAAH, to assess FAAH levels in the striatum, prefrontal cortex, and whole brains of 31 participants aged 19 to 25 who reported at least one occurrence of heavy drinking in the previous 30 days. The researchers also measured behavioral and cardiovascular responses while administering controlled intravenous alcohol infusions to participants.

Lower [11C]CURB binding, reflecting lower FAAH activity and presumably higher anandamide levels, was not related to frequency of alcohol use, but it was associated with more severe use, a greater reported craving for alcohol prior to the infusion, a greater reported “liking” of intoxication during the infusion, and reduced sensitivity to the negative effects of alcohol. “In our study, young adults with lower brain levels of FAAH reported greater stimulation and fewer intoxicating and sedating effects from drinking alcohol,” said Dr. Boileau.

Lower FAAH levels were also associated with lower heart-rate variability, a cardiac measure of parasympathetic nervous system activity. A family history of AUD, present in about half the participants, had no relationship to [11C]CURB binding.


Caption: [11C]CURB binding, reflecting brain levels of FAAH, relates to self-reported alcohol outcomes. The AUDIT measures risky or hazardous alcohol use, while the ASQ (Alcohol Sensitivity Questionnaire) measures the effects of alcohol, with higher scores indicating lower sensitivity to alcohol’s effects (Credit: Biological Psychiatry).

“Our findings are important as they suggest that FAAH levels in the brain may contribute to the maintenance of excessive drinking and to susceptibility for developing an AUD and provide a brain-based target for prevention efforts and treatment approaches,” Dr. Boileau added.

John Krystal, MD, editor of Biological Psychiatry, said of the work, “This fascinating study provides evidence linking increased endocannabinoid levels to reduced sensitivity to the negative effects of alcohol, an important risk factor for heavy drinking and AUD.”

This work suggests that FAAH levels may influence a youth’s susceptibility to alcohol misuse. These findings may guide researchers toward preventive measures to avoid AUD during this critical developmental stage, or potentially to interventions for treatment of AUD.


Notes for editors

The article is "Association Between Fatty Acid Amide Hydrolase and Alcohol Response Phenotypes: A PET Imaging Study with [11C]CURB in Heavy-drinking Youth," by Laura M. Best, Christian S. Hendershot, Jennifer F. Buckman, Samantha Jagasar, Matthew McPhee, Neel Muzumdar, Rachel F. Tyndale, Sylvain Houle, Renee Logan, Marcos Sanches, Stephen J. Kish, Bernard Le Foll, and Isabelle Boileau (https://doi.org/10.1016/j.biopsych.2022.11.022). It appears as an Article in Press in Biological Psychiatry, published by Elsevier.

Copies of this paper are available to credentialed journalists upon request; please contact Rhiannon Bugno at +1 254 522 9700 or Biol.Psych@sobp.org. Journalists wishing to interview the authors may contact Isabelle Boileau, PhD, at +1 416 535 8501 ext. 34918 or isabelle.boileau@camh.ca.

The authors’ affiliations and disclosures of financial and conflicts of interests are available in the article.

John H. Krystal, MD, is Chairman of the Department of Psychiatry at the Yale University School of Medicine, Chief of Psychiatry at Yale-New Haven Hospital, and a research psychiatrist at the VA Connecticut Healthcare System. His disclosures of financial and conflicts of interests are available here.

About Biological Psychiatry

Biological Psychiatry is the official journal of the Society of Biological Psychiatry, whose purpose is to promote excellence in scientific research and education in fields that investigate the nature, causes, mechanisms and treatments of disorders of thought, emotion, or behavior. In accord with this mission, this peer-reviewed, rapid-publication, international journal publishes both basic and clinical contributions from all disciplines and research areas relevant to the pathophysiology and treatment of major psychiatric disorders.

The journal publishes novel results of original research which represent an important new lead or significant impact on the field, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Reviews and commentaries that focus on topics of current research and interest are also encouraged.

Biological Psychiatry is one of the most selective and highly cited journals in the field of psychiatric neuroscience. It is ranked 12th out of 155 Psychiatry titles and 14th out of 274 Neurosciences titles in the Journal Citations ReportsTM published by Clarivate Analytics. The 2021 Impact Factor score for Biological Psychiatry is 12.810. www.sobp.org/journal

About Elsevier
As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems.

In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, health professionals, institutions and funders.

Elsevier employs 8,700 people worldwide. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, and health education. Researchers and healthcare professionals rely on our over 2,700 digitized journals, including The Lancet and Cell; our over 43,000 eBook titles; and our iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world.

Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com.

Media contact
Rhiannon Bugno, Editorial Office
Biological Psychiatry
+1 254 522 9700